Amphastar Pharmaceuticals, Inc.
AMPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.73 | 0.42 | 0.33 | 0.00 |
| FCF Yield | 9.58% | 4.87% | 4.79% | 6.34% |
| EV / EBITDA | 8.28 | 14.42 | 8.94 | 9.78 |
| Quality | ||||
| ROIC | 12.28% | 12.38% | 13.09% | 9.20% |
| Gross Margin | 51.08% | 54.49% | 49.87% | 45.63% |
| Cash Conversion Ratio | 1.34 | 1.33 | 0.98 | 1.55 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.62% | 13.75% | 12.57% | 10.74% |
| Free Cash Flow Growth | 18.58% | 123.09% | -7.64% | 201.30% |
| Safety | ||||
| Net Debt / EBITDA | 1.80 | 1.99 | -0.37 | -0.19 |
| Interest Coverage | 6.77 | 7.25 | 58.23 | 78.97 |
| Efficiency | ||||
| Inventory Turnover | 2.33 | 2.77 | 2.41 | 2.56 |
| Cash Conversion Cycle | 194.43 | 165.46 | 186.20 | 173.95 |